Focus on prescription uptake and payer coverage in the coming quarters — treatment effect durability at 96 weeks supports real-world use. Watch for any confirmatory trial updates that could convert accelerated approval to full approval, further derisking revenue.
Price Chart
Executive Summary
Ultragenyx announced publication of 96-week Phase 3 data for GENGLYCOS (DTX401) gene therapy in glycogen storage disease Ia, showing sustained cornstarch reduction (61% at Week 96) and maintained glycemic control. The therapy was recently FDA-approved under accelerated approval — this long-term durability data supports the approval and enhances commercial prospects in a well-defined ultra-rare patient population.
Key Facts
- GENGLYCOS (DTX401) was recently FDA approved for GSDIa patients aged 8+ under accelerated approval.
- Phase 3 96-week data showed 61% mean reduction in daily cornstarch intake in both original and crossover groups.
- 33% (original) and 42% (crossover) of participants completely eliminated nighttime cornstarch dosing by Week 96.
- 83% of DTX401-treated participants met or exceeded their own expectations for meaningful cornstarch reduction at Week 48.
- Safety profile acceptable — most common adverse events were transient liver enzyme elevations managed with corticosteroids.
- GSDIa affects approximately 1,500-2,500 patients in the U.S. and 6,000-8,000 worldwide in accessible geographies.
Financial Impact
GENGLYCOS targets an ultra-rare population (~1,500-2,500 U.S.) with high unmet need; revenue potential depends on pricing, but FDA approval with durability data de-risks launch. Prior median analyst revenue estimates for RARE could see upward revision.
Risk Factors
- Accelerated approval contingent on verification of clinical benefit in confirmatory trials.
- Competition from other gene therapies in GSDIa (none currently approved).
- Potential safety issues like immune-mediated hepatotoxicity requiring corticosteroid management.
- Limited patient population caps peak revenue potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3354584 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | 8-K | $14.85 $15.22 | ▼ −2.49% | ▼ −3.68% | $15.22 (−2.49%) |
Sep 1, 2026 4w ago | Press Release | $26.53 $15.03 | ▼ −43.35% | ▼ −43.02% | $15.22 (−42.63%) |
Aug 11, 2026 7w ago | 8-K | $26.80 $14.31 | ▼ −46.60% | ▼ −45.55% | $15.22 (−43.21%) |
Aug 4, 2026 8w ago | 8-K | $24.93 $26.53 | ▲ +6.42% | ▲ +7.02% | $15.22 (−38.95%) |
Aug 4, 2026 8w ago | Insider Cluster | $25.81 $25.81 | · 0.00% | ▲ +1.24% | $15.22 (−41.03%) |
Jun 15, 2026 15w ago | Insider Cluster | $24.85 $32.03 | ▲ +28.89% | ▲ +28.69% | $15.22 (−38.75%) |
Jun 11, 2026 16w ago | Institutional Cluster | $23.98 $34.61 | ▲ +44.33% | ▲ +42.44% | $15.22 (−36.53%) |
May 5, 2026 21w ago | Press Release | $25.93 $22.41 | ▲ +13.57% | ▲ +16.36% | $15.22 (+41.30%) |
May 1, 2026 22w ago | Insider Cluster | $24.77 $22.85 | ▼ −7.75% | ▼ −13.04% | $15.22 (−38.55%) |
Apr 2, 2026 26w ago | 8-K | $22.45 $24.69 | ▲ +9.98% | ▲ +0.10% | $15.22 (−32.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access